参考文献/References:
[1] Ahmedin J,Freddie B,Melissa M,et al.Global cancer statidtics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int.JCancer,2015,136(5):E359-E386.
[3] 邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(6):37-40,43.
Xing RQ,Wu YC,Chen HY,et al.Diognostic value of serum CA125,HE4and ROMA index in patients with ovarian cancer[J].J Mod Lab Med,2016,31(6):37-40,43.
[4] Zanotti L,Bignotti E,Calza S,et al.Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome[J].Clin Chem Lab Med,2012,50(12):2189-2198.
[5] 中华人民共和国国家卫生与计划生育委员会.WS/TA28-2013成人体重判定[S].北京:中国标准出版社,2013.
National Health and Family Planning Commission of the People's Republic of China.WS/TA28-2013.Adult weight detemination[S].Beijing:China Standard Publishing House,2013.
[6] 刘肖英.宫腔镜下分段诊刮术对子宫内膜癌的诊断价值[J].齐齐哈尔医学院学报,2016,37(2):177-179.
Liu XY.Clinical value of fractional curettage in diagnosis of endormetrial cancer under hysterossopy[J].Journal of Qiqihar University of Medicine,2016,37(2):177-179.
[7] Nikolaou M,Kourea HP,Tzelepi V,et al.The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma[J].J BUON,2014,19(1):198-202.
[8] Modarres-Gilani M,Vaezi M,Shariat M,et al.The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma[J].Cancer Biomark,2017,20(2):135-141.
[9] Dewan R,Dewan A,Hare S,et al.Diagnostic performance of serum human epididymis protein 4 in endometrial carcinoma:a pilot study[J].J Clin Diagn Res,2017,11(7):XC01-XC05.
[10] Presl J,Ovesna P,Novotny Z,et al.Importance of preoperativeknowledge of the biomarker HE4 in early-stage endometrial cancer regarding surgical management[J].Anticancer Res,2017,37(5):2697-2702.
[11] Abbink K,Zusterzeel PL,Geurts-Moesot AJ,et al.HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients[J].Tumour Biol,2018,40(2):1010428318757103.
[12] Chen Y,Ren YL,Li N,et al.Serum human epididymis protein 4 vs carbohydrate antigen 125 and their combination for endometrial cancer diagnosis:a meta-analysis[J].Eur Rev Med Pharmacol Sci,2016,20(10):1974-1985.
相似文献/References:
[1]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[2]季红兵,唐芹芳,陈思聪,等.血清肿瘤标志物HE4对肺癌的诊断价值[J].现代检验医学杂志,2017,32(02):110.[doi:10.3969/j.issn.1671-7414.2017.02.030]
JI Hong-bin,TANG Qin-fang,CHEN Si-cong,et al.Application of Serum HE4 in the Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2017,32(05):110.[doi:10.3969/j.issn.1671-7414.2017.02.030]
[3]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of
Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma
and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(05):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[4]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of
Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[5]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(05):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[6]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[7]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(05):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[8]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(05):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[9]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(05):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[10]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]